Faced by Combination Treatments (In the Pipeline)
Pozen and GlaxoSmithKline (GSK) have been trying to make a combination treatment out of two well-established drugs for migraine: GSK's Imitrex (sumitriptan) and the OTC pain reliever naproxyn. In his entry, blogger Derek Lowe talks about the difficulties involved in developing combination drugs and bringing them to market.
Panitumumbad Moves Forward (The Pharm Voice)
The FDA recently granted priority review to Amgen's human monoclonal antibody panitumumab. Blogger Gloria Gamat writes about the medication and its progress in her entry.